1663 related articles for article (PubMed ID: 17159081)
1. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
[TBL] [Abstract][Full Text] [Related]
2. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.
Palatini P; Jung W; Shlyakhto E; Botha J; Bush C; Keefe DL
J Hum Hypertens; 2010 Feb; 24(2):93-103. PubMed ID: 19458624
[TBL] [Abstract][Full Text] [Related]
3. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
Jordan J; Engeli S; Boye SW; Le Breton S; Keefe DL
Hypertension; 2007 May; 49(5):1047-55. PubMed ID: 17353513
[TBL] [Abstract][Full Text] [Related]
4. Aliskiren monotherapy does not cause paradoxical blood pressure rises: meta-analysis of data from 8 clinical trials.
Stanton AV; Gradman AH; Schmieder RE; Nussberger J; Sarangapani R; Prescott MF
Hypertension; 2010 Jan; 55(1):54-60. PubMed ID: 19917876
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial.
Andersen K; Weinberger MH; Egan B; Constance CM; Wright M; Lukashevich V; Keefe DL
Cardiovasc Ther; 2010 Dec; 28(6):344-9. PubMed ID: 20406241
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
Andersen K; Weinberger MH; Constance CM; Ali MA; Jin J; Prescott MF; Keefe DL
J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):157-67. PubMed ID: 19617271
[TBL] [Abstract][Full Text] [Related]
8. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren.
Stanton A; Jensen C; Nussberger J; O'Brien E
Hypertension; 2003 Dec; 42(6):1137-43. PubMed ID: 14597641
[TBL] [Abstract][Full Text] [Related]
9. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
[TBL] [Abstract][Full Text] [Related]
10. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats.
van Esch JH; Moltzer E; van Veghel R; Garrelds IM; Leijten F; Bouhuizen AM; Danser AH
J Hypertens; 2010 Oct; 28(10):2145-55. PubMed ID: 20625318
[TBL] [Abstract][Full Text] [Related]
11. Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively.
Stanton AV; Dicker P; O'Brien ET
Am J Hypertens; 2009 Sep; 22(9):954-7. PubMed ID: 19556972
[TBL] [Abstract][Full Text] [Related]
12. Aliskiren: an oral renin inhibitor for the treatment of hypertension.
Lam S; Choy M
Cardiol Rev; 2007; 15(6):316-23. PubMed ID: 18090068
[TBL] [Abstract][Full Text] [Related]
13. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
Villamil A; Chrysant SG; Calhoun D; Schober B; Hsu H; Matrisciano-Dimichino L; Zhang J
J Hypertens; 2007 Jan; 25(1):217-26. PubMed ID: 17143194
[TBL] [Abstract][Full Text] [Related]
14. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
Chrysant SG; Murray AV; Hoppe UC; Dattani D; Patel S; Hsu H; Zhang J
Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835
[TBL] [Abstract][Full Text] [Related]
16. Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren.
Sepehrdad R; Frishman WH; Stier CT; Sica DA
Cardiol Rev; 2007; 15(5):242-56. PubMed ID: 17700383
[TBL] [Abstract][Full Text] [Related]
17. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.
Gradman AH; Schmieder RE; Lins RL; Nussberger J; Chiang Y; Bedigian MP
Circulation; 2005 Mar; 111(8):1012-8. PubMed ID: 15723979
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial.
Andersen K; Weinberger MH; Egan B; Constance CM; Ali MA; Jin J; Keefe DL
J Hypertens; 2008 Mar; 26(3):589-99. PubMed ID: 18300872
[TBL] [Abstract][Full Text] [Related]
19. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.
Nussberger J; Aubert JF; Bouzourene K; Pellegrin M; Hayoz D; Mazzolai L
Hypertension; 2008 May; 51(5):1306-11. PubMed ID: 18391092
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension.
Gradman AH; Traub D
Rev Cardiovasc Med; 2007; 8 Suppl 2():S22-30. PubMed ID: 17401313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
